请使用支持JavaScript的浏览器!
主营:抗癌化学试剂和激酶抑制剂
℡ 4000-520-616
℡ 4000-520-616
MedKoo/AZD-1480/1/204510
产品编号:204510
市  场 价:¥0.00
场      地:美国(厂家直采)
产品分类: 蛋白类>多肽>多肽合成>
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:待定
品      牌: MedKoo
公      司:MedKoo Biosciences, Inc
公司分类:
MedKoo/AZD-1480/1/204510
商品介绍

AZD-1480

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#:204510

CAS#:935666-88-9

Description:AZD1480 is an orally bioavailable inhibitor of Janus-associated kinase 2 (JAK2) with potential antineoplastic activity. JAK2 inhibitor AZD1480 inhibits JAK2 activation, leading to the inhibition of the JAK/STAT (signal transducer and activator of transcription) signaling including activation of STAT3. This may lead to induction of tumor cell apoptosis and a decrease in cellular proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.

Price and Availability

SizePriceShipping out timeQuantity
Inquire bulk and customized quantity

Pricing updated 2021-01-23.Prices are subject to change without notice.

AZD-1480 , purity > 98%, isout of stock

Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 204510Name: AZD-1480CAS#: 935666-88-9Chemical Formula: C14H14ClFN8Exact Mass: 348.1014Molecular Weight: 348.76596Elemental Analysis:C, 48.21; H, 4.05; Cl, 10.17; F, 5.45; N, 32.13

Synonym:AZD1480; AZD-1480; AZD 1480

IUPAC/Chemical Name:(S)-5-chloro-N2-(1-(5-fluoropyrimidin-2-yl)ethyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine

InChi Key:PDOQBOJDRPLBQU-QMMMGPOBSA-N

InChi Code:InChI=1S/C14H14ClFN8/c1-7-3-11(24-23-7)21-13-10(15)6-19-14(22-13)20-8(2)12-17-4-9(16)5-18-12/h3-6,8H,1-2H3,(H3,19,20,21,22,23,24)/t8-/m0/s1

SMILES Code:CC1=CC(NC2=NC(N[C@H](C3=NC=C(F)C=N3)C)=NC=C2Cl)=NN1

Technical Data

Appearance:
white solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Certificate of Analysis:
View current batch of CoA

Safety Data Sheet (SDS):
View Safety Data Sheet (SDS)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Additional Information

AZD1480 inhibits STAT3 in tumor-associated myeloid cells, reducing their number and inhibiting tumor metastasis. Myeloid cell-mediated angiogenesis was also diminished by AZD1480, with additional direct inhibition of endothelial cell function in vitro and in vivo. AZD1480 blocked lung infiltration of myeloid cells and formation of pulmonary metastases in both mouse syngeneic experimental and spontaneous metastatic models. Furthermore, AZD1480 reduced angiogenesis and metastasis in a human xenograft tumor model. Although the effects of AZD1480 on the tumor microenvironment were important for the observed antiangiogenic activity, constitutive activation of STAT3 in tumor cells themselves could block these antiangiogenic effects, showing the complexity of the JAK/STAT signaling network in tumor progression. Together, AZD1480 can effectively inhibit tumor angiogenesis and metastasis mediated by STAT3 in stromal cells as well as tumor cells. (source: Cancer Res. 2011 Nov 1;71(21):6601-10.)  

References

1: Liu Y, Holdbrooks AT, De Sarno P, Rowse AL,Yanagisawa LL, McFarland BC, Harrington LE, Raman C, Sabbaj S,Benveniste EN, Qin H. Therapeutic efficacy of suppressing the Jak/STATpathway in multiple models of experimental autoimmune encephalomyelitis.J Immunol. 2014 Jan 1;192(1):59-72. doi: 10.4049/jimmunol.1301513. Epub2013 Dec 9. PubMed PMID: 24323580; PubMed Central PMCID: PMC3934829.

2: Sun ZL, Tang YJ, Wu WG, Xing J, He YF, Xin DM, Yu YL, Yang Y, Han P.AZD1480 can inhibit the biological behavior of ovarian cancer SKOV3cells in vitro. Asian Pac J Cancer Prev. 2013;14(8):4823-7. PubMed PMID:24083752.

3: Gu L, Liao Z, Hoang DT, Dagvadorj A, Gupta S, Blackmon S, EllsworthE, Talati P, Leiby B, Zinda M, Lallas CD, Trabulsi EJ, McCue P, GomellaL, Huszar D, Nevalainen MT. Pharmacologic inhibition of Jak2-Stat5signaling By Jak2 inhibitor AZD1480 potently suppresses growth of bothprimary and castrate-resistant prostate cancer. Clin Cancer Res. 2013Oct 15;19(20):5658-74. doi: 10.1158/1078-0432.CCR-13-0422. Epub 2013 Aug13. PubMed PMID: 23942095.

4: Plimack ER, Lorusso PM, McCoon P, Tang W, Krebs AD, Curt G, EckhardtSG. AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors.Oncologist. 2013;18(7):819-20. doi: 10.1634/theoncologist.2013-0198.Epub 2013 Jul 11. PubMed PMID: 23847256; PubMed Central PMCID:PMC3720635.

5: Chang Q, Bournazou E, Sansone P, Berishaj M, Gao SP, Daly L, Wels J,Theilen T, Granitto S, Zhang X, Cotari J, Alpaugh ML, de Stanchina E,Manova K, Li M, Bonafe M, Ceccarelli C, Taffurelli M, Santini D, Altan-BonnetG, Kaplan R, Norton L, Nishimoto N, Huszar D, Lyden D, Bromberg J. TheIL-6/JAK/Stat3 feed-forward loop drives tumorigenesis and metastasis.Neoplasia. 2013 Jul;15(7):848-62. PubMed PMID: 23814496; PubMed CentralPMCID: PMC3689247.

6: Yan S, Li Z, Thiele CJ. Inhibition of STAT3 with orally active JAKinhibitor, AZD1480, decreases tumor growth in Neuroblastoma andPediatric Sarcomas In vitro and In vivo. Oncotarget. 2013Mar;4(3):433-45. PubMed PMID: 23531921; PubMed Central PMCID:PMC3717306.

7: Bogani C, Bartalucci N, Martinelli S, Tozzi L, Guglielmelli P, BosiA, Vannucchi AM; Associazione Italiana per la Ricerca sul Cancro AGIMMGruppo Italiano Malattie Mieloproliferative. mTOR inhibitors alone andin combination with JAK2 inhibitors effectively inhibit cells ofmyeloproliferative neoplasms. PLoS One. 2013;8(1):e54826. doi:10.1371/journal.pone.0054826. Epub 2013 Jan 31. PubMed PMID: 23382981;PubMed Central PMCID: PMC3561413.

8: Couto JP, Almeida A, Daly L, Sobrinho-Simões M, Bromberg JF, SoaresP. AZD1480 blocks growth and tumorigenesis of RET- activated thyroidcancer cell lines. PLoS One. 2012;7(10):e46869. doi:10.1371/journal.pone.0046869. Epub 2012 Oct 2. PubMed PMID: 23056499;PubMed Central PMCID: PMC3462763.

9: de Groot J, Liang J, Kong LY, Wei J, Piao Y, Fuller G, Qiao W,Heimberger AB. Modulating antiangiogenic resistance by inhibiting thesignal transducer and activator of transcription 3 pathway inglioblastoma. Oncotarget. 2012 Sep;3(9):1036-48. PubMed PMID: 23013619;PubMed Central PMCID: PMC3660053.

10: Loveless ME, Lawson D, Collins M, Nadella MV, Reimer C, Huszar D,Halliday J, Waterton JC, Gore JC, Yankeelov TE. Comparisons of theefficacy of a Jak1/2 inhibitor (AZD1480) with a VEGF signaling inhibitor(cediranib) and sham treatments in mouse tumors using DCE-MRI, DW-MRI,and histology. Neoplasia. 2012 Jan;14(1):54-64. PubMed PMID: 22355274;PubMed Central PMCID: PMC3281942.

品牌介绍
MedKoo,由化学家和药学家陈清奇博士。北卡罗莱纳州的研究三角区(Research Triangle Park, 简称 RTP ),是一家以研发、生产和销售小分子抗癌化合物为主的医药科技公司,该公司的业务范围主要是为全球所有从事抗癌药物研究和开发的制药公司,高校,研究院所,政府相关机构提供与抗癌药物分子相关的产品、试剂和技术服务。
中文名MedKoo中    文美帝药库医药科技公司创立于2008年总部位于美国东海岸
自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔